Lobe Sciences (LOBE) Price & Analysis

Compare

12 Followers

LOBE Stock Chart & Stats

C$0.06

-C$0.01(-33.33%)

At close: Jan 08 4:00 PM EST

C$0.06

-C$0.01(-33.33%)

Day’s Range― - ―

52-Week RangeC$0.02 - C$0.11

Previous CloseN/A

Volume8.00K

Average Volume (3M)19.65K

Market Cap

C$14.82M

Enterprise ValueC$6.86M

Total Cash (Recent Filing)C$7.02M

Total Debt (Recent Filing)C$295.68K

Price to Earnings (P/E)―

Beta0.02

Next Earnings

May 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding269,487,120

10 Day Avg. Volume13,139

30 Day Avg. Volume19,648

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)2.94

Price to Sales (P/S)0.00

P/FCF Ratio-4.89

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Modest Leverage / Improving Balance SheetReported modest debt relative to equity in recent periods reduces near-term financing pressure versus highly leveraged peers. That lower leverage improves financial flexibility to fund R&D over the next several months and reduces default risk while the company pursues program milestones.

Improving Cash-flow TrendAlthough absolute cash flow remains negative, the TTM improvement in free cash flow signals operational trends heading the right way. Sustained improvement can extend runway, lower near-term funding needs, and make future financing less dilutive if the trend continues over multiple quarters.

Focused CNS / Psychedelic R&D And IPConcentration on CNS and psychedelic-related therapeutics positions the company in a structural growth niche with rising scientific and commercial interest. Durable value could emerge from proprietary IP or successful clinical data, enabling licensing or partnerships that strengthen long-term commercial optionality.

Bears Say

No Revenue; Persistent Operating LossesThe company operates with no recurring revenue and sizable operating losses, meaning it remains research-stage and unable to self-fund development. Over 2-6 months this structurally limits internal runway, forces reliance on external capital, and raises execution risk if fundraising stalls.

Sustained Negative Operating And Free Cash FlowPersistent cash burn requires repeated financing rounds or partnerships, increasing dilution risk and management distraction. Until FCF turns sustainably positive, cash constraints will limit trial progression, hiring, and commercialization activities, affecting medium-term ability to execute strategy.

Historical Equity Instability And Prior Negative EquityPast periods of negative equity indicate prior recapitalizations or losses that eroded shareholder value. That history signals elevated likelihood of future dilution or restructuring under stress, which undermines investor confidence and can complicate long-term financing and partnership negotiations.

Lobe Sciences News

Lobe Sciences Ramps Up R&D on Psilocin-Based Therapeutic as Cash Position Remains Solid

The latest update is out from Lobe Sciences ( ($TSE:LOBE) ). Lobe Sciences reported first-quarter fiscal 2026 results...

20d ago

Lobe Sciences Bolsters Board with Capital Markets Expert as It Builds on 2025 Momentum

Lobe Sciences ( ($TSE:LOBE) ) just unveiled an announcement. Lobe Sciences has strengthened its board of directors with...

1M ago

Lobe Sciences Strengthens Balance Sheet and Refocuses Pipeline After Leadership Overhaul

Lobe Sciences ( ($TSE:LOBE) ) has issued an update. Lobe Sciences reported a substantial improvement in its fiscal...

2M ago

Lobe Sciences Strengthens Financial Position with Debt Settlement

Lobe Sciences ( ($TSE:LOBE) ) has issued an announcement. Lobe Sciences Ltd. has completed a debt settlement involving...

4M ago

Lobe Sciences Strengthens Financial Position with Debt Settlement

Lobe Sciences ( ($TSE:LOBE) ) has provided an announcement. Lobe Sciences Ltd. has completed a debt settlement by...

4M ago

Lobe Sciences Strengthens Balance Sheet with Strategic Debt Settlement

The latest update is out from Lobe Sciences ( ($TSE:LOBE) ). Lobe Sciences Ltd. has announced a strategic...

5M ago

Lobe Sciences to Present New Therapy for Cluster Headaches at 2025 Conference

Lobe Sciences ( ($TSE:LOBE) ) has shared an update. Lobe Sciences Ltd. and Cynaptec Pharmaceuticals, Inc. are set...

6M ago

Lobe Sciences Strengthens Board with New Appointment

Lobe Sciences ( ($TSE:LOBE) ) has provided an announcement. Lobe Sciences Ltd. has appointed Marco Mastrodonato to its...

6M ago

Lobe Sciences Settles Directors’ Fees with Common Shares

Lobe Sciences ( ($TSE:LOBE) ) has provided an update. Lobe Sciences Ltd. announced the settlement of outstanding directors’...

6M ago

Lobe Sciences Closes Private Placement to Boost Therapeutic Development

Lobe Sciences ( ($TSE:LOBE) ) has shared an update. Lobe Sciences Ltd. announced the closing of a non-brokered...

6M ago

LOBE FAQ

What was Lobe Sciences’s price range in the past 12 months?

Lobe Sciences lowest stock price was C$0.02 and its highest was C$0.11 in the past 12 months.

What is Lobe Sciences’s market cap?

Lobe Sciences’s market cap is C$14.82M.

When is Lobe Sciences’s upcoming earnings report date?

Lobe Sciences’s upcoming earnings report date is May 04, 2026 which is in 70 days.

How were Lobe Sciences’s earnings last quarter?

Currently, no data Available

Is Lobe Sciences overvalued?

According to Wall Street analysts Lobe Sciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lobe Sciences pay dividends?

Lobe Sciences does not currently pay dividends.

What is Lobe Sciences’s EPS estimate?

Lobe Sciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lobe Sciences have?

Lobe Sciences has 269,487,120 shares outstanding.

What happened to Lobe Sciences’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Lobe Sciences?

Currently, no hedge funds are holding shares in TSE:LOBE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lobe Sciences

Lobe Sciences Ltd., a life sciences company, focuses on the research and development of psychedelic medicines. It develops psilocybin-based therapeutics in combination with N-acetylcysteine for the treatment of mild traumatic brain injuries and post-traumatic stress disorder, as well as devices for the efficient application of medications. The company was formerly known as Greenstar Biosciences Corp. and changed its name to Lobe Sciences Ltd. in November 2020. Lobe Sciences Ltd. is headquartered in Vancouver, Canada.